此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Low Carbohydrate Diet in Diabetic Kidney Disease

2021年6月10日 更新者:Rohana Abdul Ghani、Universiti Teknologi Mara

Effects of Low Carbohydrate Diet (LCBD) on Weight and Renal Outcome in Patients With Diabetic Kidney Disease (DKD)- A Pilot Study

The current population of type 2 diabetes mellitus (T2DM) worldwide is over 200 million and Malaysia contributes to 1.2% of that number. The prevalence of T2DM in Malaysia has approximately tripled over the last three decades from 6.3% in 1986 to 17.5% of the adult population in 2015.T2DM is a progressive disease associated with debilitating microvascular and macrovascular complications. The prevalence of chronic kidney disease (CKD) in Peninsular Malaysia was high at 9.1% of the adult population in 2011. T2DM is the leading cause of renal failure for patients commencing dialysis, increasing from 53% of new dialysis patients in 2004 to 61% in 2013. Therefore, diabetic kidney disease (DKD) is a debilitating complication which not only imposes significant health problems but also confers financial burden on affected patients. There has been increasing amount of understanding in the complexity of the relationship between T2DM and obesity. As the prevalence of both conditions continue to demonstrate a parallel rise, the influence of obesity on T2DM is further marked. Thus, this has led to greater emphasis on weight loss in the management of T2DM. More recent anti-diabetic medications including SGLT-2 inhibitors and GLP1 agonists demonstrated greater efficacy in improving glycaemic control and their ability to produce weight reduction. In addition, there has been more interest in the effects of these drugs on retardation of renal disease progression. The mechanism is unclear, either attributed by direct drug effects on renal glomerular-tubular structures, through the Renin-Angiotensin-Aldosterone-System (RAAS), or other pathways. Another pausible explanation is the significant weight loss, which has been shown to have a significant effect of attenuation of renal disease.

Weight reduction programs have long been a complex and tedious treatment plan which has inconsistent, non-duplicable and unpredictable outcomes. Most programs emphasized on medical nutrition therapy and lifestyle changes. There has been many different dietary plans which share a common goal ie to reduce calori intake whilst increasing energy expenditure. Few have been successfully reproducible, limited by either patient adherence or modest outcome.

Low carbohydrate diet is a diet plan which stresses on reducing carbohydrate intake to less than 20g daily. Numerous studies have shown that weight loss could be obtained by reduction of calori intake in either the form of carbohydrate or fat. CKD patients are recommended to consume low protein diet of less than 0.6-0.7g/kg/day with little emphasis on calori or carbohydrate intake.

This study, thus, aims to evaluate the effects of low carbohydrate and moderate fat (LCBD) in addition to low protein diet on renal disease in patients with DKD.

研究概览

地位

完全的

详细说明

This is an investigator-initiated, single center, randomized, controlled, clinical trial in Type 2 diabetes mellitus patients, comparing 16-weeks of LCBD compared to standard medical therapy in patients with DKD.

Patients would be recruited from the Endocrinology and Nephrology clinics in UiTM Medical Specialist Center. Inclusion criteria would include patients aged between 40-75 years old, diagnosis with Type 2 DM of more than 5 years with stable CKD stage 2 and 3 of more than 6 months, HbA1c of 7% - 10.5%.

Exclusion Criteria include patients with Type 1 DM, experiencing frequent hypoglycaemia, abnormal liver function tests, heart failure (New York Heart Association functional class III-IV), active systemic inflammatory disease, chronic renal failure requiring hemodialysis, active hepatic disease and collagen disease, malignancy, recent hospital admission within the past 3 months, pregnant women, breastfeeding or planning to conceive within the next year.

Following informed consent, patients would be randomised to either LCBD or low protein Diet (LPD) group.

All recruited patients will be given the standard dietary and exercise advice which will include low protein of 0.6-0.7g/kg/day and low salt diet.

In addition, patients within the LCBD will be given a prescription diet of 20g of carbohydrate daily. This will be supplemented by visual aids on carbohydrate counts of various local food. Patients would be given the option to choose their most appropriate food types which will amount to the carbohydrate count given. Patients on oral anti-diabetic treatment including insulin will advised on titrations of their medications to avoid hypoglycaemia.

The control arm will not be given any additional advice. All patients will be required to fill in a 3-day food diary during their scheduled visits which will be at 8 weeks and 16 weeks.

Clinical assessments include blood sampling of approximately 8 ml which will be done at baseline and at study end.

研究类型

介入性

注册 (实际的)

30

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Selangor
      • Petaling Jaya、Selangor、马来西亚、47000
        • Universiti Teknologi Mara

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

40年 至 75年 (成人、年长者)

接受健康志愿者

有资格学习的性别

全部

描述

Inclusion Criteria

  1. Diagnosed with Type 2 DM of more than 5 years
  2. Diagnosis of stable CKD of more than 6 months
  3. CKD stage 2 and 3
  4. HbA1c of 7% - 10.5%
  5. Patient age between 40-75 years old
  6. Able to sign informed consent

Exclusion Criteria

  1. Type 1 DM
  2. Frequent hypoglycaemia
  3. Persistent elevations of serum transminase
  4. Heart failure (New York Heart Association functional class III-IV), active systemic inflammatory disease, chronic renal failure requiring hemodialysis, active hepatic disease and collagen disease
  5. Malignancy
  6. Recent hospital admission for acute within the past 3 months
  7. Pregnant women, breastfeeding or planning to conceive within the next year

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Low carbohydrate diet (LCBD)
Subjects are given a dietary prescription of 20g of carbohydrate daily in addition to standard low protein diet of 0.6-0.7g/kg/day and low salt diet.
Subjects are provided dietary advice by the dietitians as part of the research team/ investigators
无干预:Low protein diet only (LPD)
Subjects are given the standard dietary advice of chronic kidney disease of low protein diet of 0.6-0.7g/kg/day and low salt diet.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change from baseline serum Creatinine at 12 weeks
大体时间:Study end at 12 weeks
Creatinine in micromol/L
Study end at 12 weeks
Change from baseline urine microalbuminuria at 12 weeks
大体时间:Study end at 12 weeks
Urine microalbuminuria in mmol/L
Study end at 12 weeks

次要结果测量

结果测量
措施说明
大体时间
Change from baseline HbA1c at 12 weeks
大体时间:Study end at 12 weeks
HbA1c in %
Study end at 12 weeks
Change from baseline fasting plasma glucose at 12 weeks
大体时间:Study end at 12 weeks
FPG in mmol/L
Study end at 12 weeks
Change from baseline lipid levels at 12 weeks
大体时间:Study end at 12 weeks
Cholesterol in mmol/L
Study end at 12 weeks
Change from baseline weight at 12 weeks
大体时间:Study end at 12 weeks
Weight in kg
Study end at 12 weeks
Change from baseline hip circumference (HC) at 12 weeks
大体时间:Study end at 12 weeks
HC in cm
Study end at 12 weeks
Change from baseline waist circumference (WC) at 12 weeks
大体时间:Study end at 12 weeks
WC in cm
Study end at 12 weeks
Change from baseline estimated visceral adispose tissue (Est VAT) at 12 weeks
大体时间:Study end at 12 weeks
Est VAT in %
Study end at 12 weeks
Change from baseline blood pressure at 12 weeks
大体时间:Study end at 12 weeks
Blood pressure in mmHg
Study end at 12 weeks
Change from baseline highly sensitivity C-reactive protein (hsCRP) at 12 weeks
大体时间:Study end at 12 weeks
hsCRP in nmol/L
Study end at 12 weeks
Change from baseline Interleukin-6 (IL-6) at 12 weeks
大体时间:Study end at 12 weeks
IL-6 in pg/mL
Study end at 12 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2019年3月15日

初级完成 (实际的)

2021年3月5日

研究完成 (实际的)

2021年3月5日

研究注册日期

首次提交

2021年6月1日

首先提交符合 QC 标准的

2021年6月10日

首次发布 (实际的)

2021年6月18日

研究记录更新

最后更新发布 (实际的)

2021年6月18日

上次提交的符合 QC 标准的更新

2021年6月10日

最后验证

2021年6月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Unidentified subjects' raw data is required for some journal submissions

药物和器械信息、研究文件

研究美国 FDA 监管的药品

研究美国 FDA 监管的设备产品

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

Dietary advice的临床试验

3
订阅